SEC Comment Letter 0000000000-24-011580 to Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Oct. 15, 2024 · CIK: 0001716947 · Accession: 0000000000-24-011580
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282563
Letter
October 15, 2024 Lynn Kirkpatrick President, Chief Executive Officer & Director Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, CA 92037 Re:Ensysce Biosciences, Inc. Registration Statement on Form S-3 Filed October 9, 2024 File No. 333-282563 Dear Lynn Kirkpatrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gregory J. Rubis, Esq.
Show Raw Text
October 15, 2024
Lynn Kirkpatrick
President, Chief Executive Officer & Director
Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue, Suite 201
La Jolla, CA 92037
Re:Ensysce Biosciences, Inc.
Registration Statement on Form S-3
Filed October 9, 2024
File No. 333-282563
Dear Lynn Kirkpatrick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gregory J. Rubis, Esq.